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DISCUSSION
Hyperammonemia is most commonly encountered as a complication of hepatic dysfunction. As ammonia 
levels acutely rise, neurons suffer oxidative and mechanical stress due to increased intracellular osmolarity. 
There is no numeric cutoff to predict clinical impairment, but high enough concentrations can lead to coma 
and even death. Recognition and management of non-hepatic hyperammonemia in adult patients is a great 
challenge as such cases are not often encountered, tend to be persistent, with rapid progression to a poor 
prognosis. 
CASE PRESENTATION
A 69 year-old female with no known history of inborn errors of metabolism or hepatic dysfunction 
presented with acute encephalopathy and was noted to be hyperammonemic (Serum ammonia of 860). 
She was treated with Rituximab (a monoclonal antibody against CD20) approximately 6 weeks prior for 
a cryoglobulinemic vasculitis and polyarticular inflammatory arthritis. She was initially managed with 
lactulose and rifaxamin, demonstrating improvement in mental status with decreased yet fluctuating 
ammonia levels (Approximately 150). Work up yielded no obvious explanation for the high ammonia levels. 
There were no signs of gastrointestinal 
hemorrhage, infection with urease-producing 
bacteria, seizures, intoxication of any sort, 
or hepatic dysfunction. By day 10 of her 
hospitalization, her serum ammonia gradually 
increased to levels >1000 with rapidly 
worsening and recurrent encephalopathy. 
Hyperammonemia reached a level as high as 
1370 and was refractory to renal replacement 
therapy. The patient increasingly became 
hemodynamically unstable with eventual 
expiration within 48 hrs. Further investigation 
of serum amino acid levels suggested no 
enzymatic deficiencies to diagnose urea cycle 
disorders. An autopsy was declined by family 
members.
Several medications i.e., Valproic acid, are known for their 
potential to disrupt the hepatic urea cycle, causing mild 
elevations in serum ammonia. Several reports have observed 
hyperammonemia with levels comparable to our patient’s 
following high-dose chemotherapy. While Rituximab is 
implicated in multiple cases, it has never been documented 
as being the sole culprit in patients with hyperammonemic 
encephalopathy. Given its prolonged half-life, we suspect 
that Rituximab contributed to our patient’s hyperammonemia, 
making this case iatrogenic in nature. The fact that the patient 
was not encephalopathic until serum ammonia reached levels 
>800, suggests that this was a chronic process rather than an 
acute hyperammonemia. In this case, when a CD 19 count was 
checked, it was found to be <1, indicating that Rituximab was 
still active. Proposed mechanisms suggest that Rituxumab may 
unmask mild or compensated urea cycle deficits. For instance, 
orthinthine transcarbamylase deficiency is X-linked and only 10 
percent of female carriers become symptomatic, sometimes late 
in life. Despite the non-specific findings on serum amino acid 
analysis, enzymatic deficiencies of hepatic urea cycle cannot 
be ruled out. The diagnosis of inborn errors of metabolism is 
difficult to make in the setting of an acute illness and often 
cannot be confirmed for days or sometimes months after the 
initial presentation. 
Figure 1. Algorithm for diagnosis of hyperammonemia in an adult aptient.
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Figure 1 -  Algorithm for diagnosis of hyperammonemia in an adult patient. 
